About standardization of L-lysinum 3-methyl-1,2,4-thiazolyl-5-thioacetate tablet mass
Keywords:L-lysine-3-methyl-1, 2, 4-triazolyl-5-thioacetat, Tablet Mass, Tablets, Spectrophotometry
Aim. These days despite the constant efforts to optimize treatment of CNS and cardio - vascular system diseases the problem still remains unsolved. Taking into consideration the rising cost of medical care and accompanying social problems the development and launching of new approaches, methods and treatment regimens to increase clinical effectiveness of therapy are actual. L-lysinum-3-methyl-1,2,4-thiazolyl-5-thioacetate is the representative of metabolite drugs with marked effect on the endothelium of the brain and heart blood vessels. Cardioprotective properties of the medication are aimed to ameliorate the persistence of cardiomyocytes during acute myocardial ischemia and to improve the ECG measurements. It is well known that medications for the cardiovascular disease treatment in most cases should be used during a long time period, and even lifelong. Therefore, rational drug dosage form – tablet – has been chosen for new drug. It is also known that great attention in the production of tablets is paid to stepwise quality control.
Methods and results. Therefore, the purpose of our study was the development of standardization methods of L-lysinum-3-methyl-1,2,4-triazolyl-5-thioacetatе in the tablet mass by spectrophotometry. During the work 6 series of L-lysinum-3-methyl-1,2,4-triazolyl-5-thioacetate tablet mass were studied.
Conclusions. Thus, we established that all series meet the requirements of the State Pharmacopeia of Ukraine concerning the content of the active substance. Our research resulted in the development of a sensitive, objective, reliable and reproducible method of the spectrophotometric determination of L-lysinum-3-methyl-1,2,4-triazolyl-5-thioacetate in the tablet mass.
Georgievskij, G. V. (2011) Razrabotka kompleksa fiziko-khimicheskikh metodik, obespechivayuschikh sozdanie i kontrol' kachestva original'nykh otechestvennykh preparatov, proizvodnykh 1,2,4-triazola [Development of the complex physical and chemical methods, ensuring the creation and control of the quality of the original domestic products, 1,2,4-triazole]. Zaporozhskij medicinskij zhurnal, 13(1), 58–69. [in Ukrainian].
(2008) Derzhavna farmakopeia Ukrainy [State Ukrainian Pharmacopeia], (Ad. 2). Kharkiv. [in Ukrainian].
Kovalenko, V. N. (2012) (Ed.). Kompendium. Lekarstvennye preparaty 2012 [Compendium. Medicinal Preparations. 2012]. Kyiv: Morion. [in Ukrainian].
Kucherenko, L. I., Khromylova, O. V., Moriak, Z. B., Tkachenko, G. I., & Vaschenko, O. V. (2014) Shchodo postadiinoho kontroliu vyrobnytstva tabletok [Stage control of tablets manufacturing]. Aktualni pytannia farmatsevtychnoi i medychnoi nauky ta praktyky, 2, 31–34. [in Ukrainian].
Mazur, I. A., Chekman, I. S., Belenichev, I. F., & Voloshin, N. A. (2007) Metabolitotropnye preparaty [Metabolitotropnye drugs]. Zaporozhye. [in Ukrainian].
Mazur, I. A, Belenichev, I. F., Kucherenko, L. I., Georgievskij, G. V., Chekman, I. S., Buchtiyarova, T. A., & Avramenko, N. A. (2012) Podhody k razrabotke i sozdaniyu metabolitotropnykh preparatov – proizvodnykh 1,2,4-triazola [Approaches to the development and creation of metabolitotropnyh drugs - derivatives of 1,2,4-triazole]. Nauchnye osnovy sozdaniya lekarstvennykh sredstv. Proceedings of the 12th scientific and practical seminar. Gurzuf. [in Ukrainian].
(2007) European Pharmacopoeia. Сouncil of Europe. Strasbourg.
Go A.S. Heart disease and stroke statistics 2013 update: a report from the merican Heart Association / Go A.S., Mozaffarian D., Roger V.L. et al. // Circulation. – 2013. – Vol. 127. – Р. e6–e245.
Ulu, S. T., & Elmali, F. T. (2010) Spectrophotometric method for the determination, validation, spectroscopic and thermal analysis of diphenhydramine in pharmaceutical preparation. Spectrochimica Acta Part A: Molecular and - Biomolecular
Spectroscopy, 77, 324–329. doi: 10.1016/j.saa.2010.05.031.
White, W. (2011) Blood pressure monitoring in cardiovascular medicine and therapeutscs. New Jersey: Humana Press.
How to Cite
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)